memo - Magazine of European Medical Oncology

, Volume 11, Issue 4, pp 272–275 | Cite as

The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer

  • Clemens DormannEmail author
  • Karl J. Aichberger
short review


At this year’s American Society of Clinical Oncology (ASCO) annual meeting two large phase 3 trials, the ABCSG-18 and the D‑CARE study, analysed the effects of adjuvant denosumab in breast cancer patients and reported different outcomes. Another phase 3 study, the ASTRRA trial, investigated the use of adjuvant ovarian function suppression (OFS) in high-risk premenopausal patients. This trial confirmed the benefit of OFS similar to the results of the already published SOFT/TEXT trials but raises some crucial questions on the optimal duration of OFS in these patients. The results of the SOFT/TEXT trials were also updated at this meeting.


Bisphosphonates Endocrine therapy Bone-modifying agents Denosumab Ovarian function suppression 


Conflict of interest

C. Dormann and K.J. Aichberger declare that they have no competing interests.


  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group. (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–61. Scholar
  2. 2.
    Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and other Bone-modifying agents in breast cancer: a cancer care ontario and American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(18):2062–81. Scholar
  3. 3.
    Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. J Clin Oncol. 2018;36(15_suppl):500–500. Scholar
  4. 4.
    Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D‑CARE study. J Clin Oncol. 2018;36(15_suppl):501–501. Scholar
  5. 5.
    Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433–43. Scholar
  6. 6.
    Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with ovarian suppression in Premenopausal breast cancer. N Engl J Med. 2014;371:107–18. Scholar
  7. 7.
    Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in Premenopausal breast cancer. N Engl J Med. 2015;372:436–46. Scholar
  8. 8.
    Regan MM, Francis PA, Pagani O, et al. Absolute benefit of Adjuvant endocrine therapies for Premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2‑negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34:2221–31. Scholar
  9. 9.
    Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant endocrine therapy for Premenopausal breast cancer. N Engl J Med. 2018;379:122–37. Scholar
  10. 10.
    Regan MM, Francis PA, Pagani O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) her2-negative breast cancer (BC): results from TEXT and SOFT. J Clin Oncol. 2018;36(15_suppl):503–503. Scholar
  11. 11.
    Noh WC, Lee JW, Nam SJ, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study. J Clin Oncol. 2018;36(15_suppl):502–502. Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Interne I: Internistische Onkologie, Hämatologie und GastroenterologieOrdensklinikum Linz Barmherzige SchwesternLinzAustria

Personalised recommendations